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Cancer stem cells (CSCs) represent a population of cells within the tumor able to drive tumorigenesis and known to be highly
resistant to conventional chemotherapy and radiotherapy. In this work, we show a new role for ETV7, a transcriptional repressor
member of the ETS family, in promoting breast cancer stem-like cells plasticity and resistance to chemo- and radiotherapy in breast
cancer (BC) cells. We observed that MCF7 and T47D BC-derived cells stably over-expressing ETV7 showed reduced sensitivity to the
chemotherapeutic drug 5-fluorouracil and to radiotherapy, accompanied by an adaptive proliferative behavior observed in different
culture conditions. We further noticed that alteration of ETV7 expression could significantly affect the population of breast CSCs,
measured by CD44+/CD24low cell population and mammosphere formation efficiency. By transcriptome profiling, we identified a
signature of Interferon-responsive genes significantly repressed in cells over-expressing ETV7, which could be responsible for the
increase in the breast CSCs population, as this could be partially reverted by the treatment with IFN-β. Lastly, we show that the
expression of the IFN-responsive genes repressed by ETV7 could have prognostic value in breast cancer, as low expression of these
genes was associated with a worse prognosis. Therefore, we propose a novel role for ETV7 in breast cancer stem cells’ plasticity and
associated resistance to conventional chemotherapy and radiotherapy, which involves the repression of a group of IFN-responsive
genes, potentially reversible upon IFN-β treatment. We, therefore, suggest that an in-depth investigation of this mechanism could
lead to novel breast CSCs targeted therapies and to the improvement of combinatorial regimens, possibly involving the therapeutic
use of IFN-β, with the aim of avoiding resistance development and relapse in breast cancer.
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INTRODUCTION
Breast cancer is the most frequent tumor and the leading cause
of cancer-related deaths in women [1]. Breast cancer is a highly
genetically heterogeneous disease [2], and current therapeutic
approaches are chosen based on the subtype of cancer, stage,
mass and localization of the tumors among several parameters
[3]. The most common therapeutic strategies rely both on local
(e.g., surgery and radiotherapy) and systemic treatments (e.g.,
chemotherapy, endocrine/hormonal, and targeted therapy) [4].
Hormone-dependent breast cancers, such as luminal breast
cancers, frequently become refractory to the initially effective
hormonal treatments, thus eventually requiring chemotherapy
[5]. Chemotherapy, in fact, still represents the most common
option for advanced breast cancers. However, it has been
demonstrated that chemotherapy itself, despite triggering
shrinkage of primary tumors, can enhance metastasis through
induction of EMT [6]. Moreover, cancer cells can develop drug
resistance, resulting in treatment failure and recurrence [7, 8].
Cancer stem cells (CSCs) are considered the population of cells
within the tumor able to drive tumorigenesis. CSCs are
characterized by self-renewal ability and differentiation poten-
tial, and can therefore contribute to the heterogeneity of
cancer cells within the tumor [9, 10]. Moreover, they are known
to be intrinsically highly resistant to conventional anti-cancer
agents, including chemotherapy and radiotherapy [11, 12].
Therefore, uncovering the pathways and mechanisms involved
in CSCs enrichment, development of drug resistance or other
unwanted side effects associated with chemotherapy is an
urgent and critical aim for cancer research, oriented to improve
treatment efficacy.
Using genome-wide transcriptional profiling of MCF7 human
breast adenocarcinoma-derived cells, we identified ETV7 as a
potential tumor-promoting factor among the genes more
synergistically upregulated by the combinatorial treatment with
the chemotherapeutic agent Doxorubicin and the inflammatory
cytokine TNFα [13].
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ETV7, also called TEL2 or TELB, is a member of the large family
of ETS (E26 transforming specific) transcription factors, whose
members can regulate the expression of genes involved in various
processes, such as development, differentiation, cell proliferation,
migration, and apoptosis [14, 15]. Given their role in essential
cellular functions, their dysregulation can result in severe
impairments within the cell, as demonstrated by the involvement
of ETS factors in various diseases [16–18]. In particular, many ETS
factors have been associated with cancer initiation, transforma-
tion, and metastatic spread [19–22]. The roles of ETV7 are still
poorly understood and studied, partially because of the absence
of the ETV7 gene in most rodent species, including mice [23].
However, several studies highlighted multiple roles for ETV7 in
hematopoiesis. For example, the over-expression of ETV7 in both
human and mice hematopoietic stem cells (HSCs) could increase
the proliferation and deplete HSCs [24]. Moreover, ETV7 over-
expression in human U937 cells was shown to impede monocytic
differentiation [25]. ETV7 is also recognized as an Interferon (IFN)-
stimulated gene (ISG), as its expression was shown to be induced
by type I, type II, and type III IFN treatment in different cell types
[26–28]. Elevated ETV7 expression has been associated with
several tumor types; however, the role of ETV7 in cancer has been
poorly investigated. ETV7 was shown to cooperate with Eμ-MYC in
promoting B-lymphomagenesis [29] and the forced expression of
ETV7 in mouse bone marrow was shown to cause myeloprolifera-
tive diseases, even if with a long latency, suggesting TEL2 as a
bona fide oncogene [30]. Besides, the crossing of the latest
established ETV7 transgenic mouse model with an established
leukemic mouse model revealed a remarkable acceleration in
Pten−/− leukemogenesis [31]. Further evidence supporting ETV7
pro-tumorigenic functions comes from the recent identification of
a transcriptional-independent activity of ETV7, which was shown
to physically interact with mTOR into the cytoplasm generating a
novel complex called mTORC3, which contributes to resistance to
rapamycin, an mTOR-targeting anti-cancer agent [32]. In contrast
with these observations, ETV7 was shown to act as tumor
suppressor in nasopharyngeal carcinoma by repressing SERPINE1
[33], and its downregulation was observed in drug-resistant cancer
cells [34].
Recently, Piggin and colleagues reported an average higher
level of ETV7 expression in tissues from all the breast cancer
subtypes compared to normal breast tissues, with a correlation of
ETV7 expression and breast cancer aggressiveness [35]. We have
recently demonstrated in breast cancer-derived cells that ETV7
expression can be induced by DNA-damaging chemotherapy, and
elevated ETV7 levels has been associated with reduced sensitivity
to Doxorubicin treatment, a mechanism that involve ETV7-
mediated direct repression of DNAJC15, resulting in the increase
in ABCB1 expression levels [36].
In this study, we further demonstrated the role of ETV7 in breast
cancer cell resistance to another chemotherapeutic drug, 5-
fluorouracil (5-FU) and radiotherapy. Noteworthy, we were able to
observe a remarkable increase in breast cancer stem cells content
in the cells over-expressing ETV7. We finally identified via RNA-seq
a set of type I and type II Interferon response genes that were
repressed by ETV7 as putatively responsible for the stem cells
enrichment.
In the light of these results, we propose a novel role for ETV7 as
a regulator of breast cancer stem cell-like plasticity, which is
mediated by the repression of IFN-stimulated genes and that can
be partially reverted by the stimulation of IFN response with IFN-β.
MATERIALS AND METHODS
Cell lines and culture conditions
MCF7 cells were obtained from Interlab Cell Line Collection bank (IRCCS
Ospedale Policlinico San Martino, Genoa, Italy), T47D and BT-549 cells were
received from Dr. U. Pfeffer (IRCCS Ospedale Policlinico San Martino);
HEK293T cells were a gift from Prof. J. Borlak (Hanover Medical School,
Germany), HCC70 from Dr. M.R. Maiello (INT-Fondazione G. Pascale, Naples,
Italy), MDA-MB-231 and SK-BR-3 cells were a gift from Prof. A. Provenzani
(CIBIO Department, University of Trento, Italy), while ZR-75-1 cell line was
obtained from Prof. A. Zippo (CIBIO Department).
MCF7, T47D, SK-BR-3, and HEK293T cells were grown in DMEM medium
(Gibco, ThermoFisher Scientific, Monza, Italy) supplemented with 10% FBS
(Gibco), 2mM L-Glutamine (Gibco) and a mixture of 100 U/ml Penicillin/
100 μg/ml Streptomycin (Gibco). MDA-MB-231 cells were cultured in the
same medium with the addition of 1% non-essential amino acids (Gibco).
HCC70, BT-549, and ZR-75-1 were grown in RPMI medium (Gibco)
supplemented with 10% FBS, 2 mM L-Glutamine, and a mixture of
100 U/ml Penicillin/100 μg/ml Streptomycin; BT-549 cells were also
supplemented with 1% Insulin-Transferrin-Selenium supplement (Gibco)
while ZR-75-1 cells with 1% sodium pyruvate (Gibco). Cells were grown at
37 °C with 5% CO2 in a humidified atmosphere. Cell lines were monthly
checked for mycoplasma contaminations and have recently been
authenticated by PCR-single-locus-technology (Eurofins Genomics, Ebers-
berg, Germany or DDC Medical, Fairfield, OH, USA).
Treatments
5-Fluorouracil (5-FU) (Sigma Aldrich, Milan, Italy) was used at different
concentrations and for different time points based on the specific
experiment. Recombinant human IFN-β and IFN-γ (Peprotech, Tebu-Bio,
Milan, Italy) were used at different concentrations and for different time
points based on the experiment. Navitoclax and Elacridar were obtained
from MedChemExpress (D.B.A., Milan, Italy) and Selleckchem (Aurogene,
Rome, Italy), respectively. Radiation treatment was performed using the
Elekta Precise Linear Accelerator (Elekta Oncology Systems, Crawley, UK)
for different doses and time points.
Plasmids
The expression vector pCMV6-Entry-ETV7 C-terminally tagged with DDK-
Myc tags was purchased from Origene (Tema Ricerca, Bologna, Italy). The
lentiviral vector pAIP-ETV7 was obtained by cloning using the following
primers to amplify the ETV7 gene from pCMV6-Entry-ETV7 and inserting it
into the pAIP-Empty plasmid (the tails containing restriction endonu-
cleases’ target sequences are indicated in lowercase):
Fw: aggttaacATGCAGGAGGGAGAATTGGCTA
Rv: gagaattcTTAAACCTTATCGTCGTCATCC
pAIP was a gift from Jeremy Luban (Addgene plasmid #74171; http://n2t.
net/addgene:74171; Watertown, MA, USA). Purified PCR product was
inserted into the pAIP backbone using HpaI and EcoRI restriction
endonucleases (New England Biolabs, Euroclone, Milan, Italy). Correct
cloning was checked by restriction analysis and direct sequencing (Eurofins
Genomics).
pCMV-D8.91 and pCMV-VSVg plasmids for lentiviral particles production
were obtained from Prof. Anna Cereseto, Laboratory of Molecular Virology,
CIBIO Department, University of Trento, Italy.
Viral vectors production in HEK293T
To obtain viral particles, HEK293T packaging cells were seeded into P150
dishes and transiently transfected with a mix containing 17.5 μg pCMV-
D8.91 plasmid, 7.5 μg pCMV-VSVg plasmid, 25 μg lentiviral vector contain-
ing the gene of interest and 112.5 μl PEI 2X transfection solution (Sigma-
Aldrich). After 48 h, viral vectors containing the plasmid of interest were
collected in the supernatant and filtered through a 0.45 μm filter. Vectors’
yield was quantified by the SG-PERT (Product-Enhanced Reverse Tran-
scriptase) assay with the help of Prof. Anna Cereseto’s group, Laboratory of
Molecular Virology, CIBIO Department, University of Trento, Italy.
Generation of stable pAIP-ETV7 and Empty MCF7 and T47D
cells
To obtain cell lines having a stable over-expression of the ETV7 gene, MCF7
and T47D cells were transduced with 1 RTU of the lentiviral vector pAIP-
Empty and with the lentiviral vector for the expression of the heterologous
gene ETV7, pAIP-ETV7. After 72 h, cells were split, and Puromycin (Life
Technologies) was added at a concentration of 1.5 and 2.5 μg/ml,
respectively for MCF7 and T47D cells. Each 3 days medium was replaced,
and after 4 cycles of selection, single cell cloning was performed for MCF7
cells according to the Corning protocol for cell cloning by Serial dilution in
96-well plates. During the single cell cloning procedure Puromycin
concentration was gradually reduced to 0.75 μg/ml. T47D cells did not
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undergo serial dilution but were kept as the pooled population under
Puromycin selection (1.5 μg/ml).
RNA interference
Target RNAs were silenced using small interfering RNAs (siRNAs) and the
transfection reagent INTERFERin® (Polyplus-Transfection, Euroclone).
Scrambled siRNA was used as a control. Scrambled siRNA and ETV7
targeting siRNA (#1 and #2) were purchased from Integrated DNA
Technologies (IDT, Tema Ricerca). 24 h before transfection cells were
seeded in 6-well or 96-well plates to reach 50–60% confluence. Then the
cells were transfected with 20 nM siRNA and 7 μl or 0.75 μl of INTERFERin
reagent per well, according to the used plate format. The transfection mix
was diluted respectively in 200 μl or 50 μl of OptiMEM medium (Gibco, Life
Technologies), vortexed for 10 s, incubated at room temperature for
15min, and added to the cells. Analyses on the silenced cells were
performed 72 h post-transfection.
RNA isolation and RT-qPCR
Total RNA was extracted using the Illustra RNA spin Mini Kit (GE Healthcare,
Milan, Italy), converted into cDNA with the RevertAid First Strand cDNA
Synthesis Kit following manufacturer’s recommendations (ThermoFisher
Scientific) and RT-qPCR was performed with 25 ng of template cDNA into
384-well plates (BioRad, Milan, Italy) using the Kapa Sybr Fast qPCR Master
Mix (Kapa Biosystems, Resnova, Ancona, Italy) or the qPCRBIO SyGreen 2X
(PCR Biosystems, Resnova) and the CFX384 Detection System (BioRad).
YWHAZ and GAPDH were used as housekeeping genes to obtain the
relative fold change with the ΔΔCt method as previously described [37].
Primer sequences were designed using Primer-BLAST designing tool
(https://www.ncbi.nlm.nih.gov/tools/primerblast/), checked for specificity
and efficiency, and are listed in Supplementary Table 1 (Eurofins
Genomics).
Western blot
Western blotting was performed as previously reported [38, 39]. Briefly,
total protein extracts were obtained by lysing the cells in RIPA buffer
(150mM Sodium Chloride, 1% NP-40, 0.5% Sodium Deoxycholate, 0.1%
SDS, and 50mM TrisHCl pH 8.0) and proteins were quantified with the BCA
method (Pierce, ThermoFisher Scientific); 20–50 μg of protein extracts were
loaded on appropriate 7.5%, 10% or 12% polyacrylamide gels and SDS-
PAGE was performed. Proteins were then transferred on Nitrocellulose
membranes, which were probed over-night at 4 °C with specific antibodies
diluted in 1% non-fat skim milk-PBS-T solution: ETV7/TEL2 (E-1, sc-374478),
β-Tubulin (3F3-G2, sc-53140), STAT1 (D1K9Y, Cell Signaling Technology,
Euroclone), p-STAT1 (Tyr701) (D4A7, Cell Signaling Technology), BCL-2
(100, sc-509), Survivin (D-8, sc-17779), EpCAM (ab71916, Abcam, Cam-
bridge, UK), and HSP70 (C92F3A-5, sc-66048). Antibodies were obtained
from Santa Cruz Biotechnologies (Heidelberg, Germany) when not
explicitly indicated. Detection was performed with ECL Select reagent
(GE Healthcare) using the UVITec Alliance LD2 (UVITec Cambridge, UK)
imaging system.
Cell Titer Glo viability assay
Viability assay was performed using the Cell Titer-Glo Luminescent cell
viability assay (Promega) according to the manufacturer’s instructions.
Cells were seeded in white flat 96-well plates and treated with different
concentrations of 5-FU for 72 ho. Afterward, the plates were equilibrated at
room temperature for 30min; then, 100 μl of Cell Titer-Glo reagent was
added to 100 μl of medium and left in incubation for 2 min on an orbital
shaker. Then, a luminescence measure was performed at the Infinite M200
plate reader (Tecan, Milan, Italy) or Varioskan™ LUX multimode microplate
reader (ThermoFisher Scientific). Viability was calculated as a % ratio of
viable cells treated with the indicated drug respect to DMSO control.
Vi-CELL viability assay and doubling time calculation
The cell viability after radiotherapy treatment was measured using the Vi-
CELL viability analyzer (Beckman Coulter, Brea, CA, USA), which performs
trypan blue dye exclusion method with an automated system. Cells were
seeded in 6-well plates for 24 h and then treated with different radiation
doses (2 to 10 Gy) and incubated for 72 h. Afterward, cells were harvested
using trypsin and re-suspended in PBS. Vi-CELL performed the automated
count of viable cells in the sample, allowing for viability measurement. The
viability was calculated as the percentage of viable cells with respect to the
untreated control. Doubling time was calculated with the following
formula:
Doubling time (hours)= time in culture (hours) × ln(2)/ln(# cells har-
vested/# cells seeded).
Annexin V-FITC/PI staining
Apoptosis was measured using the FITC Annexin V Apoptosis Detection
Kit I (BD Biosciences, San Jose, CA, USA) as previously described [40].
Briefly, cells were stained with an antibody against Annexin V conjugated
to FITC fluorochrome together with the vital dye propidium iodide (PI).
After the appropriate treatment, cells were harvested, washed twice with
cold PBS and re-suspended in 1× Annexin V Binding Buffer at the
concentration of 1.5 × 106 cells/ml. 100 μl of the cell suspension was then
incubated with 2.5 μl of FITC Annexin V and 5 μl of PI for 15 min at room
temperature in the dark. Subsequently, 400 μl of 1× Annexin V Binding
Buffer was added to each tube and samples were then analyzed. Flow
cytometry analysis was conducted at the CIBIO Cell Analysis and
Separation Core Facility using a FACS Canto A instrument (BD
Biosciences).
CD44/CD24 staining
The membrane expression of CD44 and CD24 cell surface markers was
measured by double staining with antibodies conjugated with fluoro-
phores and flow cytometry analysis. Cells were seeded in 6-well plate or
T25 flasks and, after the appropriate treatments, were harvested and
washed with PBS. 3 × 105 cells were re-suspended in 30 μl PBS+ 0.1% BSA
and incubated with APC mouse anti-human CD44 (cat.no 559942, BD
Bioscience) and FITC mouse anti-human CD24 (cat.no 555427, BD
Bioscience) antibodies or with their isotype controls (FITC mouse IgG2a,
k isotype, and APC mouse IgG2b, k isotype, BD Bioscience) in ice for
30min. After incubation cells were washed three times with PBS and finally
re-suspended in 300 μl PBS. Flow cytometry analysis was performed as
mentioned above.
ALDEFLUOR analysis
ALDEFLUOR kit (STEMCELL Technologies, Cologne, Germany) was used to
identify cells expressing high levels of ALDH enzyme. Experiments were
performed following the manufacturer’s instructions. Briefly, cells were
harvested and re-suspended in ALDEFLUOR Assay Buffer at the
concentration of 3 × 105 cells/ml. Then, 5 μl of activated ALDEFLUOR
reagent was added to the cells and mixed. 500 μl of the cell suspension
and reagent mixture was immediately moved to the control tube
containing 5 μl of DEAB (diethylaminobenzaldehyde) reagent, a specific
inhibitor of ALDH activity. Samples and controls were incubated for 45min
at 37 °C. After the incubation, cells were centrifuged and re-suspended in
ALDEFLUOR Assay Buffer. Flow cytometry analysis was performed at the
Tyrolean Cancer Research Institute using a FACS Canto II instrument (BD
Biosciences).
Colony formation assays
The clonogenic assay was performed seeding single cell suspension
with 2 × 103 MCF7 or 4 × 103 T47D cells in 6-well plates in complete
growth medium. Cells were let grow for 3 weeks changing the medium
twice a week. After 3 weeks, the cell colonies were gently washed with
PBS and stained by the incubation with 0.1% Crystal Violet solution in
20% methanol for 20 min. Excess staining was removed, and colonies
were washed twice in PBS. Image analysis was performed with the
Image J software in order to calculate the percentage of well’s area
occupied by colonies. To characterize the capability of transformed cells
to grow independently from a solid surface (anchorage-independent
growth), we performed soft agar colony formation assay. The wells of 6-
well plates were prepared with a layer of base agar (0.7% agarose in
DMEM complete medium+ 10% FBS). After the solidification of the
base, single cell suspension containing 1.5 × 104 (MCF7) or 2 × 104
(T47D) cells/well was rapidly mixed to the soft agar solution (0.35%
agarose in DMEM complete medium) and disposed of as a layer over the
previously prepared base agar. Finally, 1 ml of growing medium was
added on the top. Cells were let grow for 3 weeks changing the top
medium twice a week. Afterward, cells were stained with 0.1% Crystal
Violet solution in 20% methanol and washed several times with PBS 1×
to remove the excess of Crystal Violet solution. Image analysis was
performed with the Image J software in order to calculate the average
size of the colonies.
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Mammospheres culturing
Mammosphere formation assay was performed by adaptation of a
previously published protocol [41]. Briefly, to generate primary mammo-
spheres, cells were harvested with trypsin, centrifuged and re-suspended
in mammosphere medium (DMEM/F12 supplemented with 2 mM L-
glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin with the addition
of 20 ng/ml recombinant human epidermal growth factor (EGF), 10 ng/ml
recombinant human basic fibroblast growth factor (bFGF) and 1×
B27 supplement (Life Technologies). Cells were then counted and passed
through a 25G needle to obtain a single cell suspension. Then, 103 cells/
well were seeded in ultra-low attachment 24-well plates (Corning, Rome,
Italy) in 800 μl of mammosphere medium. Plates were incubated at 37 °C
for one week, and images were obtained at DM IL LED Inverted Microscope
(Leica, Wetzlar, Germany). Mammospheres were counted and split by
harvesting the mammospheres with PBS, centrifuging and re-suspending
with TrypLE Express Reagent (ThermoFisher Scientific) as an alternative to
trypsin. The single cell suspension was then again counted, and seeded at
the same starting concentration in the mammosphere medium. After
1 week, mammospheres were counted and it was possible to calculate the
Mammosphere Forming Efficiency (%) using the following equation:
MFE (%)= (# of mammospheres per well)/(# of cells seeded per well) ×
100.
Generation of ETV7 KO cells
To knock-out ETV7 with CRIPSR-Cas9 technology, ETV7-specific gRNA
sequences targeting exon 6 were designed using the CRISPOR.org web
tool [42] and cloned using sgRNA-ETV7-Ex6-1: caccgAGGGCTCATATCGGG-
TATCA and sgRNA-ETV7-Ex6-2: aaacTGATACCCGATATGAGCCCTc oligos
into the pX330-SpCas9-sgRNA-Puro vector (obtained from Prof. Anna
Cereseto, CIBIO Department, University of Trento, Italy) digested with BbsI
restriction enzyme (ThermoFisher Scientific). The correct insertion of each
gRNA into the plasmid was checked by direct sequencing (Eurofins
Genomics).
To obtain SK-BR-3 cells knock-out for ETV7, 50,000 cells per well were
seeded in 24-well plate and after 24 h transfected with 500 ng pX330-Puro-
ETV7 gRNA plasmids using Lipofectamine LTX and Plus Reagent (Life
Technologies, ThermoFisher Scientific). After 48 h post-transfection, cells
were selected with 1 µg/ml of Puromycin (Life Technologies). After 3 days
of selection, Puromycin was removed from the culture medium and once
reached confluency, cells were split and harvested for indel analysis. Single
cell cloning was performed according to the Corning protocol for cell
cloning by Serial dilution in 96-well plates. Obtained single clones were
screened by performing TIDE (Tracking of Indels by DEcomposition)
analysis. Genomic DNA was extracted using QuickExtract™ DNA Extraction
Solution (Lucigen, Middleton, WI, USA). PCR on the edited region was
performed using 5× FIREPol® Master Mix (Solis BioDyne, Tartu, Estonia) and
specific primers (TIDE-ETV7-ex6-F: ATCAGATGCTCCTGTTGGGC, TIDE-ETV7-
ex6-R: GAGCCCCATTAGTGGCTGTT), and purified products analyzed with
Sanger sequencing (Microsynth, Balgach, Switzerland). TIDE analysis and
efficiency of the editing was performed through the TIDE online platform
(http://shinyapps.datacurators.nl/tide/) using parental cells as reference
control [43].
Gene expression profiling
Total RNA from three independent biological replicates for MCF7 and T47D
cells stably transduced with pAIP-Empty and pAIP-ETV7 was checked for
quality and purity using the Agilent 2100 Bioanalyzer (Agilent Technolo-
gies, Santa Clara, CA, USA) selecting RNA extracts with a RIN (RNA integrity
number) value >8. RNA (1 μg) was then converted into cDNA libraries
according to the Illumina TruSeq Stranded mRNA Sample Preparation
Guide (Illumina, San Diego, CA, USA) following the manufacturer’s
instructions. Pair-end reads (2 × 75 bp) were generated from the libraries
using the Illumina HiSeq2500 sequencer at CIBIO NGS Core Facility
according to the standard Illumina protocol.
Raw reads were adapter-trimmed with BBDuk (sourceforge.net/projects/
bbmap/) and aligned to build version hg38 of the human genome using
STAR (version 2.5.3a [44]). Counts for UCSC annotated genes were
calculated from the aligned reads using the featureCounts function of
the Rsubread R package [45] and R (version 3.3.1). Normalization and
differential expression analysis were carried out using edgeR R package
[46]. Raw counts were normalized to obtain Counts Per Million mapped
reads (CPM). Only genes with a CPM greater than 1 in at least 3 samples
were retained for downstream analysis. Gene expression changes were
considered statistically significant with Benjamini-Hochberg FDR ≤ 5%.
Enrichment analysis for Gene Ontology—biological process category was
performed on the list of 427 downregulated genes upon ETV7 over-
expression in both cell lines using enrichGO function of the clusterProfiler R
package [47]. Gene set enrichment analysis [48] was performed in
preranked mode on the log2 fold change values estimated by edgeR
and the Hallmark collection of Molecular Signature Database (MSigDB
version 6.1, [49]). Gene sets were considered significantly enriched at
FDR ≤ 5% when using 1000 permutations of the gene sets. We defined a
signature of 22 ETV7-regulated IFN-responsive genes taking genes
significantly downregulated in both cell lines upon ETV7 over-expression
and included in the HALLMARK_INTERFERON_ALPHA_RESPONSE and
HALLMARK_INTERFERON_GAMMA_RESPONSE gene sets of MSigDB. Heat-
maps were created using standardized CPM expression values and
pheatmap R package (https://CRAN.R-project.org/package=pheatmap).
RNA-seq data from this study have been deposited at Gene Expression
Omnibus database (GEO, https://www.ncbi.nlm.nih.gov/geo/) with acces-
sion number GSE152580.
FPKM normalized expression data for TCGA breast cancer samples were
downloaded from NCI Genomic Data Commons (TCGA-BRCA project) using
the TCGAbiolinks R package [50]. ETV7 expression in different sample types
(i.e., primary tumor, metastasis, and normal tissue) and PAM50 molecular
subtypes was compared using analysis of variance (ANOVA) and post-hoc
Tukey test. Scores for the ETV7-regulated IFN-responsive gene signature in
primary tumor samples have been calculated as the average expression of
the genes comprised in the signature. Samples have been classified as
signature “high” if the ETV7-regulated IFN-responsive gene signature score
was higher than the median of the signature scores in the tumor samples,
and “low” vice versa. To evaluate the prognostic value of the ETV7-
regulated IFN-responsive gene signature, we estimated, using the
Kaplan–Meier method, the probabilities that patients would survive
(overall survival, OS; disease-specific survival, DSS), would remain free of
disease (disease-free interval, DFI) or progression (progression-free interval,
PFI). Survival data were censored at 12 years. Kaplan–Meier curves were
compared using the logrank test in the survcomp R package.
Statistical analysis
Where not specified, statistical analyses were performed using the
GraphPad Prism version 6.0 software. When appropriate, unpaired t-test
was applied for statistical significance. We selected throughout this study
the two-sample Student’s t-test for unequal variance, given that we
generally compared two conditions (i.e., treated vs. untreated samples, or
over-expression of ETV7 vs. Empty control).
RESULTS
Increased ETV7 expression decreases the sensitivity of cancer
cells to 5-FluoroUracil and to radiotherapy
We analyzed the endogenous expression levels of ETV7 among a
panel of breast cancer cell lines and we observed a higher
expression of ETV7 protein in triple negative and HER2+-derived
cell lines, compared to the luminal ones, suggesting a correlation
between the expression of ETV7 and the aggressiveness of the
tumor (Supplementary Fig. 1A). We previously showed that ETV7
over-expression in breast cancer cell lines could reduce the
sensitivity to the chemotherapeutic drug Doxorubicin [36]. To test
whether ETV7 altered expression could also affect the sensitivity to
other therapeutic treatments for breast cancer, we established
two luminal breast cancer-derived cell lines (i.e., MCF7 and T47D,
that express very low levels of endogenous ETV7) stably over-
expressing ETV7 by lentiviral transduction of a plasmid carrying
the ETV7 cDNA or the empty counterpart. The overexpression of
ETV7 in MCF7 and T47D was verified by western blot analysis
(Fig. 1A, B). We first evaluated the sensitivity of the cells to 5-
FluoroUracil (5-FU), a commonly used breast cancer chemother-
apeutic drug which, similarly to Doxorubicin, is also able to induce
ETV7 expression in breast cancer cells [36]. We analyzed the
viability of the cells after treatment with 5-FU using Cell Titer Glo
Assay, and we could observe that the cells over-expressing
ETV7 showed a remarkably reduced sensitivity to the treatment
compared to their empty counterpart, in both MCF7 (Fig. 1C) and
T47D cells (Fig. 1D). Furthermore, the opposite effect was evident
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upon ETV7 knock-down using siRNAs, which resulted in a
sensitization to 5-FU treatment in T47D cells (Supplementary Fig.
1B, C). To confirm the increased resistance to 5-FU of the cells
over-expressing ETV7, we analyzed the induction of cell death,
and in particular of apoptosis, in cells treated with 5-FU. By
Annexin V-FITC/PI staining and flow cytometry analysis, we
observed a significant reduction in PI positive (dead) cells (Fig.
1E) and a significant, but less pronounced, reduction in the
percentage of Annexin V positive (apoptotic) cells (Supplementary
Fig. 1D). A similar trend was also visible in T47D cells, however, the
reduction in apoptosis was not significant in this cell line
(Supplementary Fig. 1E, F). We previously demonstrated that the
ETV7-induced resistance to Doxorubicin involved drug efflux
mediated by the ABC transporter ABCB1, which was upregulated
at the transcriptional level both in MCF7 and MDA-MB-231 cells
over-expressing ETV7 [36]. We decided to extend our analysis to
other ABC transporters, which are commonly deregulated in drug-
resistant breast cancers, such as ABCC1/MRP1 and ABCG2/BCRP
[51–53]. We observed ABCB1, ABCC1, and ABCG2 upregulation in
MCF7 cells over-expressing ETV7 (Fig. 1F); however, no significant
differences in their expression could be shown in T47D cells
(Supplementary Fig. 1G). To further confirm the significance of
elevated levels of ABC transporters in the ETV7-mediated
resistance to 5-FU in MCF7 cells, we used Elacridar, a dual
inhibitor able to block ABCB1 and ABCG2. Viability assays showed
an increased sensitivity of MCF7 cells over-expressing ETV7 to 5-
FU when combined with Elacridar (Supplementary Fig. 1H).
Noteworthy, we were also able to detect a remarkable increase
in the expression of the anti-apoptotic proteins BCL-2 and Survivin
in MCF7 cells over-expressing ETV7 (Fig. 1G), which could explain
the decreased percentage of apoptotic cells upon 5-FU treatment
visible in MCF7 cells. Based on these results, also the combined
treatment with 5-FU and Navitoclax, a potent BCL-2 inhibitor, led
to a slight sensitization of MCF7 cells over-expressing ETV7
(Supplementary Fig. 1I). The same effect could not be observed in
T47D cells (data not shown) where neither BCL-2 nor Survivin
(already high at the baseline) were influenced by the over-
expression of ETV7 (Supplementary Fig. 1J).
In order to test whether the over-expression of ETV7 could
confer resistance to other breast cancer treatments that act
Fig. 1 ETV7 expression modulates 5-FU sensitivity in breast cancer-derived MCF7 and T47D cells. A, B Western blot analysis to measure
ETV7 protein expression in MCF7 (A) and T47D (B) cells stably over-expressing ETV7 or their empty control. HSP70 was used as loading
control. Blots were cropped for clarity and conciseness of the presentation. C, D Cell Titer Glo assay for survival analysis upon 5-FU treatment
in MCF7 (C) and T47D (D) cells over-expressing ETV7 and their empty control. The percentage of viable cells was calculated normalizing the
luminescence measures on the DMSO treated sample. E Relative percentage of PI positive cells calculated as the difference of 5-FU and DMSO
treated cells measured by Annexin V-FITC/PI staining of MCF7 Empty and MCF7 ETV7 cells treated with 5-FU 200 μM for 72 h. F RT-qPCR
analysis of ABCB1, ABCC1, and ABCG2 expression in MCF7 Empty and MCF7 ETV7 cells. G Western blot analysis of the anti-apoptotic BCL-2
and survivin protein expression in MCF7 Empty and MCF7 ETV7 cells. Tubulin was used as loading control. Bars represent the averages and
standard deviations of at least three independent experiments. On the right of each blot is indicated the approximate observed molecular
weight. *p-value < 0.05; **p-value < 0.01.
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through a different mechanism of action, we examined the
sensitivity to radiotherapy. We exposed the cells to different doses
of radiation (from 2 to 10 Gy) and measured the percentage of
viable cells and the induction of apoptosis. Interestingly, cells
over-expressing ETV7 showed a decreased sensitivity also to
radiotherapy exposure in both MCF7 and T47D cells (Supplemen-
tary Fig. 2A, B). However, significant differences between ETV7
over-expressing cells and the empty control in the induction of
apoptosis could be detected only for the lower dose of radiation
(2 Gy) in both the cell lines (Supplementary Fig. 2C–E), suggesting
that the resistance mechanism induced by ETV7 relies only
partially on the inhibition of apoptosis.
The over-expression of ETV7 alters the proliferative potential
of luminal breast cancer cells
Since the protective effect determined by ETV7 seems to be only
partially dependent on the inhibition of apoptosis, we analyzed
the proliferative potential of the cells; in fact, as both 5-FU and
radiotherapy exert their action when the cells divide, their activity
is strongly dependent on the proliferative rate of the cells. We first
analyzed the proliferative potential of MCF7 and T47D cells stably
over-expressing ETV7 by measuring their doubling time using the
ViCell instrument. We observed a significant increase in the
doubling time of MCF7 cells over-expressing ETV7 in comparison
to MCF7 Empty cells, demonstrating that cell proliferation was
slower in cells over-expressing ETV7 compared to the empty
control (Supplementary Fig. 2E). In T47D cells, this increase in the
doubling time was instead slight and not significant (Supplemen-
tary Fig. 2F). Using clonogenic assay, we could appreciate a
substantial decrease in the colony formation potential of cells
over-expressing ETV7 when grown on plastic in both MCF7 and
T47D cells (Fig. 2A, B). Therefore, the decreased proliferative rate
of the cells could also explain the increased resistance to 5-FU and
radiotherapy. Notably, despite the similar proliferation rate when
cultured in normal conditions, the growth of T47D Empty cells was
significantly reduced compared with MCF7 Empty cells when
grown at single cell density. Surprisingly, the analysis of the colony
formation ability of the cells in an anchorage-independent system
with the soft agar assay showed an opposite proliferative
behavior. Indeed, both MCF7 and T47D cells over-expressing
ETV7 formed larger colonies when grown in soft agar compared to
control (Fig. 2C, D). Nevertheless, the anchorage-independent
growth is commonly considered a pro-tumorigenic feature; thus,
these apparently contradictory results might suggest that the cells
over-expressing ETV7 could gain the ability to switch to different
proliferative behaviors based on the environmental conditions.
The expression of ETV7 affects BCSCs markers expression and
mammosphere formation
Given the observed increased resistance to 5-FU and radiotherapy,
the adaptive proliferative potential of the cells to different
environmental conditions, and data from the literature reporting
Fig. 2 Breast cancer-derived cells over-expressing ETV7 display altered proliferative potential. A, B Colony formation/clonogenic assay of
MCF7 (A) and T47D (B) Empty and ETV7 cells after 3 weeks of growth. Presented are a representative image (left) of the entire well and the
total colony area (right), calculated with the ImageJ software. C, D Soft agar colony formation assay of MCF7 (C) and T47D (D) Empty and ETV7
cells after 3 weeks of growth. On the left, a representative image of part of the well (taken at ×5 magnification) and on the right the average
colony area calculated with the ImageJ software. Indicated are the scale bars for microscopy images. Bars represent the averages and standard
deviations of at least three independent experiments. ***p-value < 0.001.
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the involvement of ETV7 in cell differentiation [25, 54], we
hypothesized that ETV7 might play a role in breast cancer stem-
like cells plasticity. To test this hypothesis, we first analyzed some
of the most commonly accepted markers for breast cancer stem
cells, including CD44 and CD24 expression and ALDH activity. We
measured the percentage of CD44+ and CD24− cells (representing
the BCSCs population) in MCF7 and T47D cells over-expressing
ETV7 or their relative control. Both the parental cell lines
presented a very low or almost absent population of CD44+/
CD24− cells; however, we could appreciate an impressive increase
in this population in both the cell lines tested upon ETV7 over-
expression (Fig. 3A, B). Importantly, the over-expression of ETV7
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could stimulate both the increase in CD44 expression and the
decrease in CD24 expression on the plasma membrane of the
cells. Among the two markers, only CD24 expression was
regulated by ETV7 at the transcript level (Supplementary Fig. 3A,
B) in both the cell lines, whereas either no significant changes or
transcript downregulation could be observed for CD44 in T47D
and MCF7 cells over-expressing ETV7 respectively, suggesting a
post-transcriptional mechanism of upregulation of CD44 expres-
sion or translocation upon ETV7 over-expression (Supplementary
Fig. 3A, B). We then evaluated the activity of ALDH via ALDEFLUOR
assay kit. Here again, we observed a very low population of ALDH+
cells in the parental cell lines, but, either a decrease in this already
small population or no significant differences were observed in
response to ETV7 over-expression in MCF7 (Supplementary
Fig. 3C) and T47D (Supplementary Fig. 3D) cells, respectively.
Thus, the over-expression of ETV7 seems to drive a strong
polarization of the analyzed breast cancer cells toward a more
cancer stem-like cell phenotype represented by the CD44+/CD24−
population.
Furthermore, to confirm our findings, we analyzed the
expression of a recognized additional marker for breast cancer
stemness, the adhesion molecule EpCAM. Noteworthy, we could
appreciate a strong increase in EpCAM protein expression in ETV7
over-expressing cells (Fig. 3C and Supplementary Fig. 3E).
To verify whether modulating the expression of ETV7 in the
opposite direction could also affect the population of CD44+/
CD24− cells, we silenced the expression of ETV7 in the aggressive
triple negative BC-derived cell line MDA-MB-231, which is known
from the literature to present almost exclusively CD44+/CD24−
cells [55]. We knocked-down ETV7 expression using two different
siRNAs (siETV7#1 and siETV7#2), and we confirmed their activity at
mRNA and protein level (Supplementary Fig. 3F, G). Noteworthy,
although MDA-MB-231 cells do not express high level of ETV7,
which does not account for their CD44/CD24 expression levels, in
both samples silenced for ETV7 we observed a population of cells
with decreased CD44 membrane expression compared to the
scramble control, suggesting that tuning the expression of ETV7
could bi-directionally affect the population of CD44+/CD24− cells
(Supplementary Fig. 3H). We then tested whether the knock-out of
ETV7 in SK-BR-3 cells, which express high levels of ETV7 and are
characterized by a high percentage of CD44+/CD24− cells, could
also affect this population. Notably, in a clone of SK-BR-3 cells
knock-out for ETV7 we were able to observe a strong increase in
CD24 expression, with consequent reduction in CD44+/CD24−
population (Supplementary Fig. 3I, J).
Moreover, another feature of breast cancer stem cells is their
potential to form spheres (i.e., mammospheres) when grown in
non-differentiating and non-adherent conditions. We measured
the mammosphere formation efficiency (MFE) of MCF7 cells over-
expressing ETV7 and the relative empty control cells, and we
noticed a significant increase in the MFE of MCF7 cells over-
expressing ETV7 compared to the control (Fig. 3D, E). We then
tested the propagation potential of mammospheres by passaging
them in culture, and we could appreciate the ability of cells over-
expressing ETV7 to generate second, third, and fourth-generation
mammospheres (Fig. 3F). These data confirm that the over-
expression of ETV7 in breast cancer cells can enhance the cancer
stem-like cell properties and thus suggest a role for ETV7 in breast
cancer stem-like cell plasticity.
Unfortunately, we could not obtain any mammosphere from
T47D, which, when grown in non-adherent and non-
differentiating conditions, could form only aggregates of cells
with unorganized structure (data not shown).
ETV7 induces the repression of a signature of interferon
responsive genes
In order to identify the molecular mediators of the biological
effects caused by the over-expression of ETV7, we performed a
transcriptome analysis on MCF7 and T47D cells over-expressing
ETV7 or the relative empty plasmid by RNA-seq. Indeed, being
ETV7 a transcription factor, we expect it to exert most of its effects
via transcriptional control. The analysis of transcriptional data
identified 5,387 genes differentially expressed (DEGs) in MCF7 and
1,883 in T47D cells over-expressing ETV7 as compared to empty
controls, respectively (Fig. 4A). For each cell line, it was possible to
observe a similar number of up- and downregulated genes, with
721 genes that were commonly regulated in the two cellular
systems (427 commonly downregulated and 294 commonly
upregulated genes), and a lower number of genes which were
inversely regulated in MCF7 and T47D cells (Fig. 4A).
Given that most of the biological effects previously observed
in cells over-expressing ETV7 were common to both the cell lines,
we focused our subsequent analyses on the common DEGs. In
particular, as ETV7 is known to be a transcriptional repressor, we
were interested in the commonly downregulated genes, which
could be regulated by ETV7 in a more direct way. Interestingly,
the most significant terms obtained by the gene ontology
analysis of common downregulated DEGs involved innate
immune response and inflammatory response, with several
terms referred to the pathogen/viral entry into the host
(Supplementary Fig. 4A). Moreover, gene set enrichment analysis
(GSEA) highlighted “Interferon_alpha_response” (Fig. 4B) and
“Interferon_gamma_response” (Fig. 4C), i.e., the Hallmark gene
sets comprising genes involved in the cellular response to type I
or type II Interferons, respectively, as the only common
significantly repressed gene sets enriched in cells over-
expressing ETV7. From these analyses, we then obtained a
signature of Interferon responsive genes significantly down-
regulated (FDR ≤ 0.05) in both the cell lines upon ETV7 over-
expression (ETV7-regulated IFN-responsive gene signature;
Fig. 4D). We selected for validation the genes of the signature
whose Fold Change was lower than −2 in both the cell lines, and
we were able to confirm by RT-qPCR the repression of the entire
list in MCF7 (Fig. 4E) and T47D (Supplementary Fig. 4B) cells over-
expressing ETV7, with the sole exception of CFB, whose
significant repression could be validated only in T47D cells.
Furthermore, to verify whether the regulation of these IFN-
responsive genes can be bi-directionally regulated by ETV7, we
silenced ETV7 both in MCF7 and T47D parental cells using siRNAs
and analyzed the expression of some of the studied IFN-
responsive genes (i.e., APOL6, IFI35, and IFITM2). Notably, we
showed a significant upregulation of the three genes in response
Fig. 3 The over-expression of ETV7 influences the expression of breast cancer stem cell markers and mammosphere formation efficiency.
A, B CD44-APC and CD24-FITC staining and flow cytometry analysis in MCF7 (A) and T47D (B) Empty and ETV7 cells. On the left, a
representative dotplot of the results obtained at FACS Canto A; the histogram on the right summarizes the percentage of CD44+/CD24− cells
in Empty and ETV7 over-expressing cells. C Western blot analysis of EpCAM expression in MCF7 Empty and MCF7 ETV7 cells. The correct band
is indicated with an arrow. HSP70 was used as a loading control. On the right of each blot is indicated the approximate observed molecular
weight. D A representative image of first-generation mammospheres obtained from MCF7 Empty and MCF7 ETV7 cells, respectively. The scale
bar is indicated. E The percentage of mammosphere formation efficiency (% MFE) in MCF7 Empty and ETV7 calculated as the number of
mammospheres per well/number of cells seeded per well × 100. F % MFE in second-, third-, and fourth-generation mammospheres obtained
by passaging the mammospheres every 7 days. Bars represent the averages and standard deviations of at least three independent
experiments. *p-value < 0.05; **p-value < 0.01; ***p-value < 0.001.
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to ETV7 knock-down (Fig. 4F and Supplementary Fig. 4C, D),
strengthening the role for ETV7 in their regulation at the
transcript level. The same analysis was further expanded to other
BC cell lines (i.e., MDA-MB-231, SK-BR-3, and HCC-70), confirming
also in these additional cellular models the role of ETV7 in the
negative regulation of these IFN genes (Supplementary Fig. 4E–I).
We then decided to test the responsiveness of the selected
genes to type I and type II IFN treatment in MCF7 cells. In
particular, we chose to use IFN-β as type I IFN, given the previous
data in literature suggesting a negative role for IFN-β in breast
cancer stemness [56, 57], and IFN-γ as type II IFN, being the only
member of this subfamily. Since, as mentioned above, ETV7 itself
is a well-recognized Interferon-stimulated gene (ISG) [26, 28], we
first analyzed its expression in response to IFN-β and IFN-γ in
MCF7 cells. As expected, we observed a robust and significant
induction of ETV7 expression in response to both types of IFNs,
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with a peak of induction at 8 h for IFN-β and 24 h for IFN-γ,
confirming that ETV7 is strongly responsive to IFNs also in the
breast cancer-derived MCF7 cell line (Fig. 4G).
We then analyzed the expression of the validated genes
repressed by ETV7 in response to IFN-β and IFN-γ. Interestingly, all
the analyzed genes, with the exception of ICAM1, were more
responsive to IFN-β than to IFN-γ (Fig. 4H and Supplementary
Fig. 4J).
IFN-β treatment partially reverses the ETV7-dependent breast
cancer stem-like cells plasticity
Given the observation that the over-expression of ETV7 could
modulate breast cancer stem-like cells content in both MCF7 and
T47D cells, and that this effect was reflected by a strong repression
of a signature of IFN-responsive genes at the transcriptional level,
we hypothesized that, if the repression of the IFN-responsive
genes was responsible for the observed biological effects, the
stimulation of their expression by treatment with IFNs could
possibly reverse the breast cancer stem-like cell plasticity related
to ETV7 expression. Therefore, we performed long-term treat-
ments of MCF7 Empty and ETV7 cells with either IFN-β or IFN-γ
and analyzed the mammosphere formation efficiency of the cells.
Strikingly, IFN-β, but not IFN-γ, could strongly inhibit the
mammosphere formation capacity of MCF7 cells over-expressing
ETV7 already at the first generation (Fig. 5A). Moreover, IFN-β
treatment completely abolished the ability of the cells to
propagate in vitro, as MCF7 cells over-expressing ETV7 could not
generate second, third and fourth-generation mammospheres
(Fig. 5B and Supplementary Fig. 5A, B). Our hypothesis was further
supported by the analysis of CD44+/CD24− cell population in
MCF7 and T47D cells treated with either IFN-β or IFN-γ for 2 weeks.
Indeed, treatment with IFN-β, but not with IFN-γ, could revert the
increase in CD44+/CD24− cells observed in the cells over-
expressing ETV7 (Fig. 5C, D). These data suggest that the over-
expression of ETV7 could drive breast cancer stem-like cells
plasticity through the repression of a panel of IFN-responsive
genes, as the treatment with IFN-β, to which most of the validated
genes are responsive, could reverse the breast cancer stem cells
enrichment. This concept is further supported by the observation
that, even in MCF7 cells over-expressing ETV7 where a strong
repression in the expression of the IFN-responsive genes was
visible, most of these genes were still responsive to the treatment
(Supplementary Fig. 5C).
ETV7-dependent repression of IFN-responsive genes shows
prognostic value in breast cancer
To test whether the repression of the IFN-responsive genes
expression mediated by ETV7 could be endowed with a
prognostic significance in breast cancer patients, we first analyzed
the expression of ETV7 in the breast cancer samples of the TCGA
project (see “Materials and methods” for technical details). In
accordance with a previous report [35], we could confirm a
significantly higher expression of ETV7 in metastatic and primary
solid tumors as compared to normal tissue (Fig. 6A). Moreover, the
expression of ETV7 increased according to cancer aggressiveness,
and it was significantly higher in basal-like samples compared to
the other molecular subtypes (Fig. 6B). Based on these findings,
we then examined whether the expression of ETV7-repressed IFN-
responsive gene signature could have a prognostic value in breast
cancer patients (TCGA cohort). Noteworthy, Kaplan–Meier plots
revealed that the low expression of the signature was significantly
correlated with a lower probability of disease-specific survival
(DSS, Fig. 6C), overall survival (OS, Fig. 6D), disease-free interval
(DFI, Fig. 6E) and progression-free interval (PFI, Fig. 6F). We may
speculate that the ETV7-dependent repression of the IFN-
responsive genes could drive a more aggressive form of breast
cancer, which according to our preliminary data, could possibly be
responsive to IFN-β treatment.
DISCUSSION
ETV7 is a poorly studied transcriptional repressor of the ETS family
of transcription factors, which is mainly considered as an
oncoprotein [24, 30]. Recently, it was shown that the expression
of ETV7 is significantly higher in breast cancer tissues compared to
normal breast [35], suggesting a possible role for ETV7 in breast
cancer pathogenesis; however, the functions and impact of ETV7
expression in breast cancer are still to be elucidated. We have
recently published a novel mechanism of ETV7-mediated resis-
tance to the chemotherapeutic agent Doxorubicin which involves
the downregulation of DNAJC15 tumor suppressor leading to an
increased expression of ABCB1 efflux pump [36]. In this work, we
expanded the effects of enhanced ETV7 expression on breast
cancer progression and resistance to conventional anti-cancer
drugs. Indeed, we demonstrated that the over-expression of ETV7
in MCF7 and T47D cells was also associated with reduced
sensitivity to other types of standard treatments, such as 5-FU
(Fig. 1C–E and Supplementary Fig. 1C–F) and radiotherapy
(Supplementary Fig. 2A–D). In MCF7 cells, this increased resistance
was accompanied by the induction of some ABC transporters
frequently responsible for chemoresistance in breast cancer (i.e.,
ABCB1, ABCC1, and ABCG2) (Fig. 1F), the increased expression of
the anti-apoptotic proteins BCL-2 and Survivin (Fig. 1G), which
were not observed in T47D cells over-expressing ETV7 (Supple-
mentary Fig. 1G, J). A common feature observed in both MCF7 and
T47D cells over-expressing ETV7 which could mediate the
observed decreased sensitivity to 5-FU and radiotherapy treat-
ments is the decreased proliferative potential observed in ETV7
over-expressing cells, since both 5-FU and radiotherapy efficacy
depend on cell division (Fig. 2A, B). Indeed, the reduced cell
proliferation, together with the observed increase in the expres-
sion of ABC transporters and anti-apoptotic proteins, are common
drug resistance-associated properties [58–60].
Interestingly, we also noticed that the proliferation rate of the
cells underwent a switch when the cells were grown in an
anchorage-independent manner. In particular, the colony
Fig. 4 The over-expression of ETV7 causes the repression of a signature of IFN-response genes. A A Venn diagram showing the number of
differentially expressed genes (DEGs at a False Discovery Rate (FDR) ≤ 0.05) in the comparison between MCF7 and T47D cells over-expressing
ETV7 and their respective controls. B, C Gene Set Enrichment Analysis (GSEA) of MCF7 and T47D cells over-expressing ETV7 vs MCF7 and T47D
controls. Enrichment plots for Type 1 Interferon response (B) and Type 2 Interferon response (C) gene sets of the Hallmark Collection. The
Normalized Enrichment Score (NES) represents the degree of the enrichment of the gene set; the negative sign indicates that the gene set is
downregulated in cells over-expressing ETV7. D Heatmaps showing the standardized expression level of genes comprising the ETV7-regulated
IFN-responsive gene signature in MCF7 (left) and T47D (right) cells. E RT-qPCR experiments for the validation of genes of the ETV7-regulated
IFN-responsive signature with a Fold Change (FC) <−2 in MCF7 Empty and ETV7 cells. Bars represent the averages and standard deviations of
at least three biological replicates. F RT-qPCR analysis of the expression of a group of IFN-responsive genes in MCF7 cells transfected with
ETV7 targeting siRNA #1 and siRNA #2 or the scrambled control. **p-value < 0.01; ***p-value < 0.001. G RT-qPCR analysis of normalized ETV7
expression relative to untreated control in MCF7 cells treated with 5 ng/ml IFN-β (red) or IFN-γ (blue) at different time points. H RT-qPCR
analysis of the normalized expression of the genes regulated by ETV7 (IFI35, HERC6, APOL6) in MCF7 cells treated with 5 ng/ml IFN-β (red) or
IFN-γ (blue) at different time points. Bars represent the averages and SEM of at least three biological replicates.
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formation potential in soft agar was significantly higher in cells
over-expressing ETV7, whereas an opposite effect was observed
when the colony formation efficiency was measured on plastic-
support (Fig. 2A, B vs. Fig. 2C, D). This observation suggests a
plastic behavior of the cells over-expressing ETV7, which can
adapt their proliferative potential to the environmental conditions.
Moreover, anchorage-independent growth is considered a pro-
tumorigenic feature [61], suggesting that the over-expression of
ETV7 may induce pro-tumorigenic effects in breast cancer cells.
Given these observations, and the literature data reporting anti-
differentiation roles for ETV7 [29], we hypothesized that the
altered expression of ETV7 could affect the breast cancer stem
cells population. Noteworthy, when we analyzed the CD44+/
CD24low/- BCSCs subpopulation in MCF7 and T47D cells over-
expressing ETV7, we detected a remarkable increase (from ~1% in
cells transfected with the empty vector to >30% in both cell lines
over-expressing ETV7) (Fig. 3A, B), with a respective change in
CD44 and CD24 membrane expression upon ETV7 knock-down or
knock-out in cell lines characterized by a high percentage of
CD44+/CD24low/− population (Supplementary Fig. 3H, J). This
fascinating finding could be explained by the fact that CSCs can
also originate from differentiated non-stem cells, through de-
differentiation of normal somatic cells acquiring stem-like
characteristics and malignant behavior via genetic or heterotypic
alterations, such as EMT [62]. We also evaluated the effect of ETV7
over-expression on the protein levels of EpCAM, often used to
identify BCSCs. Interestingly, both MCF7 and T47D cells over-
expressing ETV7 showed and increased expression of EpCAM (Fig.
3C and Supplementary Fig. 3E), further strengthening our findings
on the ETV7-mediated breast cancer stemness. Another recog-
nized marker for BCSCs is the aldehyde dehydrogenase (ALDH), a
family of cytosolic enzymes responsible for the detoxification by
oxidation of intracellular aldehydes and are involved in the retinol
to retinoic acid oxidation during stem cells differentiation [63].
Surprisingly, using ALDEFLUOR assay, we found that MCF7 and
T47D over-expressing ETV7 had a reduced or unchanged ALDH
activity, respectively (Supplementary Fig. 3A, B), in contrast with
what mentioned above. However, CD44+/CD24low/− BCSCs can
overlap only partially with ALDH+ BCSCs, and present different
properties. Liu and colleagues demonstrated that BCSCs can exist
in two distinct states: a mesenchymal-like and an epithelial-like
state [64]. According to their work, CD44+/CD24low/− cells belong
to the mesenchymal-like BCSCs, are primarily quiescent, highly
invasive, and are localized at the tumor invasive front. Conversely,
the ALDH+ cells are the epithelial-like BCSCs, are highly
proliferative, characterized by the expression of epithelial markers,
and are localized more centrally within the tumor mass [64]. This
model can somehow explain the contradictory data about CSCs
and the EMT state, as some studies suggest a commonality
between the two states [65], whereas others suggest that these
processes are mutually exclusive [66], and this is further proof of
cancer stem cell plasticity in BC, as BCSCs can switch between the
two states.
In order to investigate genome-wide the mechanisms responsible
for the effects of ETV7 observed in culture, we performed RNA-seq
analysis on MCF7 and T47D cells over-expressing ETV7 and the
relative controls. Since ETV7 is known to act as a transcriptional
repressor, we focused our analysis mainly on the commonly
downregulated genes and gene sets in MCF7 and T47D cells over-
expressing ETV7. Interestingly, the enrichment analysis revealed
significant repression of a signature of Interferon-stimulated genes
(ISGs) (Fig. 4B, D and Supplementary Fig. 4A). Notably, we validated
these data with qPCR analyses in MCF7 and T47D cells over-
expressing ETV7 (Fig. 4E, F and Supplementary Fig. 4B) and we
confirmed that the silencing of ETV7 could restore their expression in
several BC-derived cells (Supplementary Fig. 4C–I). Therefore, we
hypothesized that, if ETV7 exerts its effect on breast cancer stem cell
plasticity via the repression of IFN response genes, inducing the re-
expression of these genes might possibly reverse the observed
effects. We thus selected IFN-β and IFN-γ as representative of type I
Fig. 5 IFN-β treatment reverses the breast cancer stem-like cell enrichment induced by ETV7. A, B Percentage of first (A) and second (B)
generation mammosphere formation efficiency (% MFE) in MCF7 Empty and ETV7 cells in response to 5 ng/ml IFN-β or IFN-γ calculated as
number of mammospheres per well/number of cells seeded per well × 100. C, D Histograms summarizing the percentage of CD44+/CD24−
cells measured by CD44-APC and CD24-FITC staining and flow cytometry analysis in MCF7 Empty and ETV7 cells (C) or T47D Empty and ETV7
cells (D) treated with 5 ng/ml IFN-β and IFN-γ for 2 weeks. A representative dot plot of the results obtained at FACS Canto A in T47D cells is
shown on the right. Bars represent the averages and standard deviations of at least three biological replicates. *p-value < 0.05; **p-value < 0.01.
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Fig. 6 The expression of ETV7 and ETV7-repressed interferon signature genes have prognostic value in breast cancer. A, B ETV7
expression in TCGA BRCA samples classified by tissue type (A) and PAM50 molecular subtype (B). Plot whiskers extend to the most extreme
data point which is no more than 1.5 times the interquartile range from the box. The significance is calculated with ANOVA and post-hoc
Tukey test. *p-value < 0.05; ***p-value < 0.001. C–F Kaplan–Meier curves for TCGA breast cancer patients stratified according to the average
expression of ETV7-regulated IFN-responsive gene signature. Curves represent the probability of disease-specific survival (DSS) (C), overall
survival (OS) (D), disease-free interval (DSI) (E) and progression-free interval (PFI) (F). p-values are calculated with logrank test.
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and type II IFN, respectively, and tested the responsiveness of the
obtained signature of ISGs in MCF7 cells. Interestingly, despite the
fact that several genes were classified as type II ISGs in the MSigDB
Hallmark collection, almost all of the analyzed genes were more
responsive to IFN-β than to IFN-γ (Fig. 4H and Supplementary Fig. 4J).
This effect can suggest the presence of a novel negative feedback
loop, given that ETV7 itself is induced in response to IFNs as we also
confirmed by RT-qPCR (Fig. 4G). However, ETV7 expression did not
affect STAT1 induction in response to IFN treatment, suggesting that
the repression of the ISGs may act independently, or possibly
downstream, on STAT1 activation (Supplementary Fig. 6).
Interestingly, we showed that the prolonged treatment of the
cells with IFN-β, but not with IFN-γ, was able to rescue the effects
on CSCs content tested both as CD44+/CD24low/− population (Fig.
5C, D) and by mammospheres formation ability (Fig. 5A, B and
Supplementary Fig. 5A, B). The fact that IFN treatment, and in
particular IFN-β, but not IFN-γ, can reverse the observed effects on
CSC plasticity, supports the hypothesis that ETV7 mediates its
functions via the repression of ISGs, as IFN-β is a stronger inducer
of the ETV7-repressed genes compared to IFN-γ. Our results
support the previous observations, which showed that immune-
repressed triple-negative breast cancers (TNBC) lacking endogen-
ous IFN signaling were highly recurrent, therapy-resistant, and
characterized by CSC-like features [67, 68]. Moreover, Doherty and
colleagues recently showed that the treatment with IFN-β, which
was able to restore the IFN signaling, could revert the CSCs
properties observed in transformed mammary epithelial cells,
suggesting it as a potential therapeutic approach for TNBC
treatment [56]. Our data strengthen these observations and
provide a novel role for ETV7 in breast cancer stem-like cell
plasticity. Lastly, we identified a gene signature of ETV7 down-
regulated genes endowed with prognostic relevance in breast
cancer patients, suggesting a role for ETV7 and for this set of
genes as possible biomarkers for BC prognosis (Fig. 6).
Taken collectively, our data reveal that the altered expression of
ETV7 can affect the sensitivity of BC cells to some anti-cancer
agents (i.e., Doxorubicin, 5-FU, and radiotherapy) and that it may
accomplish this task by modulating the breast cancer stem cells
plasticity. In light of these results, we can speculate that targeting
CSCs in BC patients with IFNs (particularly IFN-β) prior (or in
combination with) the administration of chemo/radiotherapy
could enhance the efficacy of anti-cancer standard treatments.
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